Article Information
History
- June 29, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Cheleka A.M. Mpande1,
- Munyaradzi Musvosvi1,
- Virginie Rozot1,
- Boitumelo Mosito1,
- Timothy D. Reid1,
- Constance Schreuder1,
- Tessa Lloyd1,
- Nicole Bilek1,
- Huang Huang2,
- Gerlinde Obermoser2,
- Mark M. Davis2,
- Morten Ruhwald3,4,
- Mark Hatherill1,
- Thomas J. Scriba1,*,
- Elisa Nemes1,*,
- ACS Study Team1
- 1South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa
- 2Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California, United States of America
- 3Statens Serum Institut, Copenhagen, Denmark
- 4Foundation of Innovative New Diagnostics, Geneva, Switzerland
- ↵*Corresponding authors Address correspondence to Elisa Nemes, elisa.nemes{at}uct.ac.za and Thomas Scriba, Thomas.scriba{at}uct.ac.za; Telephone: +27 21 406 6791
Posted June 29, 2020.
Mycobacterium tuberculosis-specific T cell activation identifies individuals at high risk of tuberculosis disease
